Laricitrin
Based on 1 Customer Validation
Laricitrin is a natural product with multiple biological activities. Laricitrin inhibits the phosphorylation and DNA-binding activity of STAT3, and downregulates the expression of IL-10. Laricitrin acts as an immunomodulator to regulate the differentiation, maturation and function of dendritic cells (DCs). Laricitrin inhibits the migration and invasion of lung cancer cells, and ameliorates lung cancer progression. Laricitrin can be used in research related to hypertension and lung cancer.
For research use only. We do not sell to patients.
- Purity: 99.36%
- CAS No.: 53472-37-0
- Formula: C16H12O8
- Molecular Weight:332.26
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
STAT3 |
IL-10 |
IL-12 |
Laricitrin binds to regions adjacent to the ACE active site, active site residues of renin, and core active site residues of ATR; it inhibits LPS-induced phosphorylation and DNA-binding activity of STAT3 in human CD14+ monocytes, and downregulates the expression of IL-10[1].
Laricitrin (2 μM; 5 days) restores the differentiation, maturation and cytokine balance (increased IL-12, decreased IL-10) of human CD14+ monocyte-derived dendritic cells impaired by the conditioned medium of A549 or CL1-5 lung cancer cells[1].
Laricitrin (2 μM) restores the T cell activation function of dendritic cells treated with conditioned medium from human A549 or CL1-5 lung cancer cells, promotes the proliferation of naive CD4+ T cells, and shifts the cytokine secretion profile from a Th2-type to a Th1-type pattern[1].
Laricitrin (2 µM; 1 h pretreatment of dendritic cells followed by 24-48 h chemoattractant exposure) inhibits the migration of human lung adenocarcinoma H1395 and HCC2935 cells induced by H1395-TADC-CM, BaP-H1395-TADC-CM, HCC2935-TADC-CM, and BaP-HCC2935-TADC-CM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human lung adenocarcinoma H1395 cells, human lung adenocarcinoma HCC2935 cells
-
Concentration:2 µM (pretreated on dendritic cells)
-
Incubation Time:1 h (dendritic cell pretreatment); 24, 48 h (conditioned media incubation as chemoattractant)
-
Result:Inhibited the migration of human lung adenocarcinoma H1395 and HCC2935 cells induced by H1395-TADC-CM, BaP-H1395-TADC-CM, HCC2935-TADC-CM, and BaP-HCC2935-TADC-CM.
Laricitrin (30 mg/kg; i.p.; 3 times over 5 days) potentiates the anticancer activity of Cisplatin (HY-17394) (2.5 mg/kg; i.p.; weekly) in LLC-bearing mice, resulting in fewer lung tumor nodules than Cisplatin treatment alone[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 53472-37-0
-
Appearance Solid
-
Molecular Weight 332.26
-
Formula C16H12O8
-
Color Light yellow to yellow
-
SMILES
O=C1C(O)=C(C2=CC(OC)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Chang WA, et al. Laricitrin ameliorates lung cancer-mediated dendritic cell suppression by inhibiting signal transducer and activator of transcription 3. Oncotarget. 2016 Dec 20;7(51):85220-85234. [Content Brief]
[2]. Chang WA, et al. Laricitrin suppresses increased benzo(a)pyrene-induced lung tumor-associated monocyte-derived dendritic cell cancer progression. Oncology letters. 2016 Mar;11(3):1783-1790. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Laricitrin Related Classifications
HY-N8840 Related Classifications
Powered by Bioz